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Abstract
Over-expression of Snail1 gene transcriptional repressor promotes an epithelial-to-mesenchymal transition in epithelial
tumour cell lines. Expression of Snail1 RNA has been associated to the pathogenesis of a number of malignancies; however,
the lack of good monoclonal antibodies against this protein has precluded a definitive analysis of Snail1 protein. In this
study, we aimed to determine the expression of this transcriptional factor in colorectal tumours. Using a Snail1 well-
characterized monoclonal antibody developed in our laboratories we have analyzed by immunohistochemistry a cohort of
162 human colorectal tumours. Ninety tumours (56%) showed nuclear expression in the tumoral tissue and the adjacent
stroma; in 34 (21%), Snail1 was detected just in the stroma, whereas in only 4 the expression of Snail1 was detected in the
tumoral tissue and the stroma was negative. No correlation was found between the presence of Snail1 in the tumour and
tumour stage; however, a trend (p = 0.054) was detected when the expression of this factor in the stroma was considered.
Snail1 immunoreactivity in this compartment was associated with presence of distant metastasis (p = 0.006). Moreover,
expression of Snail1 in the tumor stroma correlated with lower specific survival of cancer patients (p = 0.011). Interestingly,
this correlation was also detected in stage I and II tumors. Therefore, our results indicate that the presence of nuclear Snail1
immunoreactive cells in the stroma may be an informative indicator of prognosis of colon tumours especially useful in those
corresponding to lower stages and identify a new marker suitable to label activated stroma in colon tumours.
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Introduction
Colorectal carcinoma is one of the most common malignancies
worldwide [1]. The prognosis of colorectal cancer is fundamentally
based on stage. However, some patients eventually die from
recurrence and dissemination of cancer soon after surgery,
whereas others patients with disease at a similar stage do not.
This difference may be the result of the different malignant
potential of cancers classified in the same stage. Therefore
identification of novel biological markers related to tumour
aggressiveness is needed to recognize high risk patients who would
benefit from adjuvant therapy and to identify new molecular
targets for the development of novel treatments.
Local invasion of carcinomas involves cellular changes associ-
ated with a process known as epithelial-mesenchymal transition
(EMT), also critical for some early events in embryonic
development [2]. The main hallmark of this process is the loss
of E-cadherin expression mainly caused by repressed transcription
of this gene (CDH1) [2]. Expression of several transcriptional
repressors has been shown to down-regulate CDH1 transcription
[3]. Among them, an essential role for Snail1 has been highlighted
by the general induction of the expression of this gene during
EMT in many cell lines and especially by the lack of E-cadherin
down-regulation during gastrulation of Snail1 deficient murine
embryos [3]. The current working model supposes that Snail1 is
required for triggering E-cadherin down-regulation and EMT but
not for silencing E-cadherin gene expression in mesenchymal cells
[3]. According to this essential role of Snail1 in the modulation of
EMT, expression of this factor has been associated to several
pathological processes, such as tumour invasion [3] and renal
fibrosis [4].
Snail1 expression in adult tissues has been performed by
analyzing its corresponding RNA. However, the subcellular
localization and stability of this transcriptional factor are sensitive
to Ser/Thr phosphorylation [5–9] and Lys oxidation of this
protein [10]. For instance, GSK-3b-dependent phosphorylation of
Snail1 protein translocates this protein to the cytosol, where it is
not active, and it is subsequently degraded [5–9]. Therefore, Snail
mRNA and protein levels do not necessarily correlate. Moreover,
Snail1 protein analysis has been hampered by the lack of good
antibodies capable to detect this factor in paraffin-embedded
samples. We have recently developed a monoclonal antibody
(MAb) suitable for this analysis [11]. A preliminary study indicated
that Snail1 protein was observed in a small percentage of tumour
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cells, normally placed at the tumour-stroma interface [11]. Snail1-
positive cells were also detected in the stroma [11]. In this article
we report the results of a more extensive study performed with 162
colon tumours.
Results
We have analyzed the expression of Snail1 protein in 162
tumours obtained from colon cancer patients (Table 1). This
analysis was carried out using a specific MAb that only detects one
band in western blot, reacts with Snail1 protein and not with
Snail2 [11,12]. The specificity of this antibody for the analysis of
paraffin-embedded sections was demonstrated by the morpholog-
ical location of the positive cells detected in embryonic samples
and also by the lack of immunoreactivity in sections from Snail1
KO embryos [13]. Expression of Snail1 was detected in 128 of the
162 tumours analysed (79%) and not in the normal tissue obtained
from distal areas of the same patients (Table 2). A tumour was
considered positive when at least 1% of the cells in the analyzed
area showed Snail1 staining. This threshold was chosen in order to
compare ours results with previous analysis in other tumours using
this cut-off [14]. Only cells with nuclear reactivity were considered
to be positive. Cytosolic staining was occasionally detected in our
analyses in epithelial cells. This cytosolic reactivity was not
considered since, although it may be due to a residual expression
of Snail1 protein, this transcriptional factor has been shown to be
inactive in the cytosol [5–8], rendering its expression outside the
nucleus irrelevant.
Representative sections obtained in our analysis are shown in
Figure 1. The number of positive cells in the different samples was
variable; from tumours with few Snail1 expressing cells (Figure 1A
or M) to some cases were Snail1 was massively expressed
(Figure 1J). Nuclear immunoreactivity was normally associated
with areas of invasion, but not all the invasion fronts were positive.
Nuclear expression of Snail1 was more abundant in the stroma.
Reactivity in this compartment was observed in spindle fibroblast-
like cells and also in histiocytes detected in areas of inflammation.
In 34 cases (Figure 1A–E) the immunoreactivity was observed only
in the stroma and tumour cells were negative for Snail1
expression. In most cases, positive stromal cells were placed close
to the tumoral cells (Figure 1B and C). In 90 samples, positive cells
were observed both in the tumour and in the stroma (Figure 1G–
P). Frequently, nuclear expression of Snail1 in tumour cells
corresponded to areas where the tumour was losing its epithelial
structure (Figure 1G, H and I). In some cases, it was not possible to
determine if the immunoreactive cell was a carcinoma or stromal
cell (for instance, see labelled cell at Figure 1H).
Some other examples of cells presenting Snail1 nuclear
expression are also shown. For instance, we detected Snail1
immunoreactive cells migrating out of degenerating glands
(Figure 1G, I or N) or in the glandular lumen (Figure 1M). In
some occasions Snail1 expressing cells seemed to be entering a
vessel, as the labelled cell in Figure 1O. Reactivity in endothelial
cells were often detected, as shown in Figures 1O and P. The high
expression of Snail1 detected in areas of inflammation (Figure 1P)
was also remarkable. Although not common (only 4 cases), the
presence of nuclear reactivity in the tumour but not in the stroma
was also observed (see Figure 1F). These four samples showed a
very low number of positive cells.
We analyzed if Snail1 nuclear expression correlated with
clinicopathologic features. Table 2 shows the presence of Snail1
in the tumour and stroma of colorectal tumours at different stages.
No significant correlation was found between the expression of
Snail1 in the tumour and the tumour stage when we compared
columns T+/S2 and T+/S+ versus T2/S2 and T2/S+ in
Table 2. However, when we considered immunoreactivity in the
stroma (T2/S+ and T+/S+ versus T+/S2 and T2/S2), a trend
was obtained with regard to the tumour stage, with a p = 0.053.
Since all stage IV tumours presented Snail1-positive cells in the
Table 1. Characteristics of 162 patients with colorectal
cancer.
Characteristic N (%)
Age, mean (6SD) 68.3 (611.5)
Sex
Female 67 (41.3%)
Male 95 (58.6%)
Tumor site
Right Colon 43 (26.5%)
Left Colon 85 (52.5%)
Rectum 34 (21%)
Differentiation of tumor
Well 2 (1.2%)
Moderate 152 (93.8%)
Poor 8 (4.9%)
Histological type
Adenocarcinoma (NOS) 143 (88.3%)
Mucinous 19 (11.7%)
Lymph node metastasis
Negative 80 (49.3%)
N1 51 (31.4%)
N2 31 (19.1%)
Stage
I 22 (13.5%)
II 54 (33.3%)
III 65 (40.1%)
IV 21 (12.9%)
doi:10.1371/journal.pone.0005595.t001
Table 2. Expression of Snail1 in tumor and stroma according
to tumor stage.
Snail1 expression: tumor (T) or stroma (S)
T2/S2 T2/S+ T+/S2 T+/S+ Total
Tumor Stage I 4 7 1 10 22
II 13 8 2 31 54
III 17 13 1 34 65
IV 0 6 0 15 21
Total 34 34 4 90 162
Snail1 immunoreactivity was determined in the stromal or carcinoma cells
corresponding to colorectal tumours classified in the different stages.
According to Snail1 expression, tumours were classified as presenting Snail1
expression both in the tumour and stroma (T+/S+), just in the tumour (T+/S2),
just in the stroma (T2/S+) or not present in either of these compartments (T2/
S2).
doi:10.1371/journal.pone.0005595.t002
Snail1 in Colon Tumours
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Figure 1. Nuclear Snail1 protein expression in colon carcinomas. Expression of Snail protein was determined as indicated in Methods in
samples corresponding to colon carcinomas using MAb EC3. Micrographs of several representative stained sections are shown. Panels A–E
corresponded to tumours considered positive only in the stroma; panel F, just in the tumour, and panels G–P; in both compartments. The arrow in
panel H labels a cell that cannot be clearly classified as tumoral or stromal. In panel O the arrow points at a cell entering a vessel. Bars indicate
magnification.
doi:10.1371/journal.pone.0005595.g001
Snail1 in Colon Tumours
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stroma (Table 2), a correlation (p = 0,006) was established between
the presence of distant metastasis at the moment of the diagnosis
and Snail1 immunoreactivity in the stroma. No significant
associations were observed between Snail1 expression in any of
the two compartments and other parameters (lymph node
metastasis, degree of differentiation or tumour site).
The correlation between Snail1 expression and patients’
survival was also determined. Specific survival was determined
since this parameter reflects the nature of cancer more accurately
than overall survival.). As expected according to the higher
expression observed in stage IV tumours, presence of Snail1 in
the stroma correlated with a lower survival (p = 0.011, see
Figure 2, left panel). Additional immunoreactivity in the tumour
did not decrease the p value (not shown), giving further
indication that the presence of Snail1 in the stroma was the
most relevant parameter. Moreover, lower survival was also
observed when we compared negative tumours with tumours
showing Snail1 reactivity only in the stroma (Figure 2, right
panel).
We also determined whether Snail1 expression in the stroma
of tumours of different stages also correlated with lower survival,
regardless its presence in the tumour. This analysis could not be
carried out in stage IV tumours since all our specimens were
positive for Snail1. We did not find a significant correlation in
stage III tumours; however the association between Snail1
immunoreactivity in the stroma and lower survival was
significant for stage I and II tumours (Figure 3). Unfortunately,
more elaborated statistical analysis could not be performed due
to the lack of events in Snail1 negative tumours. However, a
Kaplan-Meier analysis was also performed after classifying
Snail1-positive samples according to the degree of expression,
determined as indicated in Methods. This analysis was only
performed on stage II tumours and also demonstrated that
presence of Snail1 protein in the stroma correlated with lower
survival (Figure 3).
Discussion
Nowadays it is well accepted that carcinomas must be
considered as a complex tissue where signals derived from the
stroma play a relevant role in the progression of the disease.
Tumour stroma is a complex medium composed of different types
of fibroblasts and immune cells recruited by the carcinoma cells.
Communication between the tumoral and the stromal compart-
ments has been demonstrated; for example chemokines derived
from the tumour can promote the activation of stromal fibroblasts
[15–17]. Conversely, factors secreted by these cancer activated
fibroblasts or other components of the activated stroma have been
shown to increase the invasive capability of tumour cells [15,16]
and have been associated to colon tumour progression [18].
Therefore, the determination of specific tumoral markers, not only
in the tumoral cells but also in the associated stroma is particularly
interesting for determining the progression of this disease.
Using a monoclonal antibody developed in our laboratories, we
have analysed the nuclear expression of Snail1 transcriptional
factor in human colon tumours. As indicated, this protein works as
an E-cadherin-gene repressor, required for triggering EMT. In our
analysis Snail1 protein was not detected in normal colonic tissue.
However, in a broad percentage of biopsies from colon carcinomas
(124/162) it was present in the stroma, or both in the stroma and
the tumoral tissue. The percentage of immunoreactive cells in the
specimens was variable but expression of Snail1 in positive cases
was focalized and detected in areas of invasion or mucosal erosion
and ulceration (see Figure 1P). Such a higher expression of Snail1
in areas of ulceration has been detected by other authors using a
different MAb [19] and might be due to the response of epithelial
cells to cytokines secreted by recruited inflammatory cells.
Analyses of Snail1 gene expression in different types of human
tumours have been reported [see 3 for a review]. These studies
indicate that Snail1 is associated with invasion, secondary
metastasis and poor prognosis [3]. For instance, in breast tumours
expression of Snail1 has been associated with relapse [20].
Figure 2. Kaplan-Meier specific survival curves for colon carcinoma patients according to Snail1 expression in the stroma.
Discontinuous line represents negative Snail1 immunoreactivity; continuous line, Snail1 positive immunoreactivity. The graphics compare tumours
where expression of Snail1 was observed in the stroma with respect to negative ones, regardless of the immunoreactivity in the tumour (left); and
with only reactivity in the stroma with respect to negative biopsies (right). The p values are indicated.
doi:10.1371/journal.pone.0005595.g002
Snail1 in Colon Tumours
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However, most of these studies have been carried out measuring
RNA levels and should be interpreted with care since the
expression of Snail1 mRNA and the corresponding protein levels
do not always correlate, since Snail1 protein is very unstable and
its half-life is controlled either by phosphorylation or lysine
oxidation (see introduction). Moreover, the cellular localization of
Snail1 is also subjected to a post-translational control by
phosphorylation [5]. As far as this is concerned, we must
emphasize that in our analysis we have only considered as
Snail1-positive those cells presenting immunolabelling in the
nucleus. The diffuse staining detected occasionally in the cytosol
in some epithelial cells was not considered, since Snail1 is not
active in this compartment. Another factor that introduces an
additional difficulty in the analysis of Snail1 RNA is the existence
of a human retrogene with a similar sequence to Snail1 that may
interfere with the reverse transcription PCR analysis of Snail1
RNA [21].
The study of Snail1 protein has been hindered by the lack of
antibodies suitable for the analysis of paraffin-embedded samples.
Several commercial antibodies are available although their
specificity has not been fully determined. Anyhow, recent reports
have started to analyze Snail1 in human tumours using better
characterized antibodies. Becker and co-workers have determined
the expression of Snail1 in adenocarcinomas of the upper
gastrointestinal tract without detecting any significant association
with clinicopathologic parameters [19]. However, these same
authors have detected an association of Snail1 expression with
tumour grade in endometrioid carcinomas [22] and with overall
surviving in ovarian carcinomas [14]. In these studies the
association with survival was detected with Snail1 expression in
the tumour whereas we found it with its presence in the stroma. It
is possible that this different association of Snail1 with clinico-
pathologic parameters is due to the cell-specific expression of other
proteins necessary for the repression by this factor of key targets in
Figure 3. Specific survival of stage I, II and III colon tumour patients according to Snail1 expression in the stroma. The presence of
Snail1 in the stroma of stage I, II and III tumours is represented as continuous lines; dotted lines correspond to stroma-negative tumours. In the lower
left panel, expression of Snail1 in the stroma was considered as low or high according to the criteria indicated in Methods. The significance is
indicated in each category.
doi:10.1371/journal.pone.0005595.g003
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epithelial cells, such as E-cadherin. For example, expression of
Lysyl oxidase-like 2 protein in Snail1- positive tumour cells may
modulate the effects of Snail1 in colon tumour cells, as it has been
demonstrated in a recent study with squamous cell carcinomas
[23].
In our analysis, the percentage of stage IV tumours showing
Snail1 expression in the stroma was significantly higher than for
the other stages, suggesting a role for this factor in the promotion
of metastasis [3]. In our studies, the most relevant association was
detected with the specific survival. Expression of Snail1 in the
stroma correlated with lower specific survival in stage I and II
tumours that display variable prognosis. The capability to predict
recurrence at these stages would have a clinical relevance because
markers for this process have not been identified yet. Therefore,
the expression of Snail1 would potentially help to identify patients
with a worse prognosis and maybe suitable for chemotherapy, a
treatment not applied to all early stages colorectal tumours.
As mentioned in the results, the percentage of Snail1 positive
cells was low in the tumours. Even considering this low number of
reactive cells, we detected a significant correlation with survival,
although the tumours presenting higher expression showed lower
specific survival. A range of possibilities may explain how Snail1
expression in the stroma, even at lower levels, decreases survival. It
is possible that Snail1 is expressed in cells that already have
undergone an almost complete EMT and have already evaded
from the tumour. Therefore, although Snail1 expression would be
limited to the cells that are going through (or have just undergone)
EMT, analysis of this factor in the stroma will indicate how many
cells have escaped from the tumour and are capable of invading
the basal lamina and later on colonize distant target organs.
Another alternative would be that higher expression of Snail1 in
the stroma may reflect the activation of this compartment.
Therefore, a Snail1 immunoreactive stroma would be able to
create a richer microenvironment for the progression of colon
tumours than a Snail1-negative one. These two possibilities are not
mutually exclusive and probably reflect the situation in different
areas of the tumour, or at different stages of its evolution. They
also agree with the idea that an activated stroma is responsible for
generating EMT-induced signals that will favour invasion of
tumours cells, as it has been elegantly discussed [24]. In any case
they may explain the lower survival of patients showing Snail1
expression in the stroma and support the use of this parameter for
the prognosis of stage II colon tumours.
Materials and Methods
Patients and tumour samples
We selected 162 patients with colorectal adenocarcinoma who
underwent surgery of the primary tumour between January 1995
and December 2001 at the Hospital del Mar, Barcelona. Tumours
were obtained from the Tumour Bank from the Servei de
Patologia from Hospital del Mar and donated with the written
patient’s informed consent. The analysis of the samples was
approved by the Ethical Committee for Clinical Experimentation
of the IMAS (Barcelona, Spain). Clinical data and follow-up were
obtained from the review of the patient’s medical records and from
the Tumour Registry. Postoperative adjuvant chemotherapy with
5-fluorouracil was performed for stage III patients; stage IV
patients received palliative chemotherapy. Follow-up of the
patients was carried out for at least eight years after surgery.
The clinicopathologic characteristics of the patients at the moment
of the diagnosis are listed in Table 1. Microscopic confirmation of
diagnosis, tumour type and histological grade was carried out by
pathologists of Servei de Patologia, Hospital del Mar. Patient
staging was classified according to the International Union against
Cancer tumour-node metastasis criteria [25]. Specific survival was
calculated from time of surgery of the primary tumour to patient
death secondary to its colorectal cancer.
Tissue microarray construction and
immunohistochemistry
In order to prepare the tissue microarray, formalin-fixed,
paraffin-embedded tissue blocks of colorectal tumours were
retrieved from the archives of the Servei de Patologia from
Hospital del Mar. Multiple areas of invasive carcinoma and
different histological patterns of the tumours (cribiform, mucinous,
poorly-differentiated), adenomatous lesions from the same surgical
sample, and normal mucosa, located far from the infiltrating
tumour, were identified on corresponding haematoxylin-eosin-
stained slides. The tissue blocks were transferred to a recipient
‘‘master’’ block using a Tissue Microarrayer. Each core was 0.6-
mm wide spaced 0.7–0.8 mm apart.
Immunohistochemical analysis of Snail1 protein was performed
as previously described by using MAb EC3 [11]. Tissues were
sectioned at 4 mm, deparaffined and rehydrated using xylene and
a series of graded ethanol. For antigen unmasking, sections were
immersed in Tris EDTA buffer (pH 9), boiled for 20 min, cooled
at room temperature for 20 min, and rinsed with PBS.
Immunohistochemical staining was carried out with anti-Snail1
MAb EC3 [11] at 1/300 dilution using the CSAII Amplification
System (Dako, Glostrup, Denmark), in a Dako Autostainer.
Sections were counterstained with haematoxylin.
Scoring and Statistic al Analysis
Immunohistochemical evaluation was conducted by two
investigators who had no knowledge of the clinicopathologic data.
Snail1 staining was graded as positive only when nuclear staining
was detectable. In each area we separately considered the
immunoreactivity of epithelial (tumour) cells and stromal cells
(fibroblasts and, in areas of inflammation, histiocytes). Tumour or
stroma was considered positive when at least 1% of the cells in the
analyzed area showed nuclear staining. A similar threshold for
considering a tumour Snail1 positive has been used by other
authors [14] when determining the expression of this factor in
ovarian tumours. To be considered negative the number of cells in
the paraffin block has to be lower than 1%. When analysed
tumour microarrays, three sections were analysed in order to avoid
false negatives; to be classified as negative the average number of
the three sections of the microarray had to show lower than 1%
immunoreactive cells. When a semi quantitative evaluation was
performed, the staining was scored according to the nuclear
staining in a scale of 0 to 300. This was the result of multiplying
the percentage of positive cells (from 1 to 100%) and the intensity
of immunoreactivity (1 to 3). These samples were categorized into
three groups: negative expression; low expression (,10); and high
expression (.10).
Survival data were analyzed according to the Kaplan-Meier
method and tested for significance between the groups with the log
rank test. A p value lower than 0.05 was considered significant.
The associations between Snail1 expression and other clinico-
pathologic variables were assessed by the Chi-square test using
categorical variables. All statistical analyses were carried out using
StatView for Windows version 5.0 (SAS Institute Inc).
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